Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Engineered Virus Shows Promise in Some Brain Tumors

A clinical trial testing a common virus modified to generate a specific immune response dramatically reduced deadly brain tumors in a small group of patients and extended their survival for years, but most other patients had only limited success. . . . → Read More: Engineered Virus Shows Promise in Some Brain Tumors

Biotechs Collaborate on Immunotherapies in $1.2B Deal

Two biotechnology companies developing cancer therapies harnessing the immune system are partnering on new treatments for solid tumor and blood-related cancers. . . . → Read More: Biotechs Collaborate on Immunotherapies in $1.2B Deal

Neuro Therapy Company Spins-Off, Gains $20.8M Funding

A company developing treatments for cognitive impairment and Alzheimer’s disease is starting-up in Belgium, with a technology and financial backing from local and global businesses and investors. . . . → Read More: Neuro Therapy Company Spins-Off, Gains $20.8M Funding

Biotech, Univ. Lab Partner on Stem Cells for Alzheimer’s

A biotechnology company specializing in stem cell therapeutics is licensing a process from Texas A&M University to produce exosomes — cellular delivery packages — from adult stem cells as possible therapies for Alzheimer’s disease. . . . → Read More: Biotech, Univ. Lab Partner on Stem Cells for Alzheimer’s

Pharma Maker Crowdsourcing for Drug Delivery Partners

The global pharmaceutical company AstraZeneca is looking for collaborators to develop treatments for disease using nucleic acids delivered with cell-penetrating peptides. . . . → Read More: Pharma Maker Crowdsourcing for Drug Delivery Partners

Engineered T-Cells Show Extended Leukemia Remission

A clinical trial shows a patient’s immune system cells, modified to add cancer-fighting proteins, can extend high remission among children with a type of leukemia for as long as 12 months, but also with high rates of adverse effects. . . . → Read More: Engineered T-Cells Show Extended Leukemia Remission

T-Cell Therapy Company Gains $100M in Venture Funds

A 2 year-old company developing treatments for cancer and other diseases that activate or suppress the immune system with genetically engineered T-cells is raising $100 million in its first venture funding round. . . . → Read More: T-Cell Therapy Company Gains $100M in Venture Funds

Start-Up Licenses Children’s Myopia-Control Contact Lens

A start-up enterprise spun-off from Hong Kong Polytechnic University is licensing the technology for a customized contact lens that controls and prevents further myopia in children. . . . → Read More: Start-Up Licenses Children’s Myopia-Control Contact Lens

Institute, Company Partner on Implanted Neuro Device

A research center in Switzerland and medical engineering company in Germany are developing an implanted device to measure signals and treat disorders affecting the brain. . . . → Read More: Institute, Company Partner on Implanted Neuro Device

Celgene Acquires Cancer Drug Start-Up in $7B Deal

The biopharmaceutical company Celgene Corp. is acquiring Impact Biomedicines Inc., a developer of drugs to treat a type of blood-related cancer, in a deal valued as much as $7 billion. . . . → Read More: Celgene Acquires Cancer Drug Start-Up in $7B Deal